Functional roles of circular RNAs during epithelial-to-mesenchymal transition

Bing-Qing Shang1,2†, Min-Le Li1,2†, Hao-yu Quan1,2†, Ping-Fu Hou1,2, Zhong-Wei Li1,2, Su-Fang Chu1,2, Jun-Nian Zheng1,2* and Jin Bai1,2*

Abstract
Cancer has become a major health issue worldwide, contributing to a high mortality rate. Tumor metastasis is attributed to the death of most patients. Epithelial-to-mesenchymal transition (EMT) plays a vital role in inducing metastasis. During EMT, epithelial cells lose their characteristics, such as cell-to-cell adhesion and cell polarity, and cells gain motility, migratory potential, and invasive properties to become mesenchymal stem cells. Circular RNAs (circRNAs) are closely associated with tumor metastasis and patient prognosis, as revealed by increasing lines of evidence. CircRNA is a type of single-stranded RNA that forms a covalently closed continuous loop. CircRNAs are insensitive to ribonucleases and are widespread in body fluids. This work is the first review on EMT-related circRNAs. In this review, we briefly discuss the characteristics and functions of circRNAs. The correlation of circRNAs with EMT has been reported, and we discuss the ways circRNAs can regulate EMT progression through EMT transcription factors, EMT-related signaling pathways, and other mechanisms. This work summarizes current studies on EMT-related circRNAs in various cancers and provides a theoretical basis for the use of EMT-related circRNAs in targeted management and therapy.

Keywords: Epithelial-to-mesenchymal transition, CircRNAs, Metastasis, Biomarker

Background
Epithelial-to-mesenchymal transition (EMT) is an important cellular event widely involved in physiologic and pathologic processes, including embryonic organ development [1, 2], wound healing, and tumor metastasis [3, 4]. During EMT, epithelial cells lose their characteristics, such as cell-to-cell adhesion and cell polarity. Instead, cells gain motility, migratory potential, and invasive properties, thereby becoming mesenchymal stem cells. The understanding of the mechanism of EMT progression has improved. The expression of epithelial markers, such as E-cadherin (E-cad), decreases and that of mesenchymal markers, such as N-cadherin (N-cad), vimentin, and claudin, increases during EMT progression. Multiple EMT transcription factors (EMT-TFs), including the Snail, Twist, and Zeb families, converge into EMT regulation. In addition to EMT-TFs, several signaling pathways have been identified, i.e., the transforming growth factor β (TGF-β)/Smad, Wnt/β-catenin, and Hedgehog signaling pathways. Noncoding RNAs can modulate EMT through EMT-TFs and EMT-related signaling pathways. Noncoding RNAs comprise a wide range of RNAs with different characteristics. This review mainly discusses the modulation of circRNAs in EMT progression.

Circular RNA (circRNA) is a type of single-stranded RNA that forms a covalently closed continuous loop. In circRNAs, unlike the known linear RNAs, the 3′ and 5′ ends normally present in an RNA molecule are linked. In 1976, the first circRNA was found in an RNA virus [5, 6]. In 1991, Nigor et al. [7] observed circRNAs in eukaryotes. CircRNAs were considered as an accidental byproduct until Jeck WR found two types of circRNA formations in 2013 [8]. With the rapid development of sequencing technology, the characteristics and functions of circRNAs have been revealed. Numerous circRNAs have been identified in humans. circRNAs exist widely in tissues, serum, and urine. CircRNAs have been identified as a determinant factor in many human diseases, including cardiovascular...
system diseases, neurological disorders, and cancer. Moreover, several studies have demonstrated that circRNAs can serve as prognostic biomarkers because of their characteristics [9–13].

This review summarizes current studies on EMT-related circRNAs in various cancers and provides a theoretical basis for the use of EMT-related circRNAs in targeted management and therapy.

### Biogenesis of circRNAs

CircRNAs are classified into three categories: exon circRNA (ecRNA), circular intron RNA (ciRNA), and exon–intron circRNA (EIciRNA). In 2013, Jeck proposed that exon skipping and intron pairing are events that narrow the distance between splice sites and facilitate the back-splicing of pre-mRNA. This phenomenon results in circRNAs that lack 3′ and 5′ ends. In ecRNA and EIciRNA formation, circRNAs are linked by a 3′–5′ phosphodiester bond, whereas ciRNAs are linked by a 2′–5′ phosphodiester bond [14]. In general, the generation of linear RNA involves removing introns and linking exons in sequence. The competitive relationship between linear splicing and back-splicing determines the fate of hnRNA. As such, circRNA formation is precisely controlled. The two introns flanking the circularized exons, which have been found to be enriched in Alu repeats, can increase the efficiency of circularization [8, 15]. Some proteins regulate the biogenesis of circRNA, including RNA binding proteins (RBPs) and the spliceosome [16, 17]. The regulation of circRNA formation by proteins is complex and consists of positive and negative modulations. For example, quaking can promote circRNA biogenesis by binding to specific sites in the intron region [18]. In contrast, some proteins are negatively associated with the formation of circRNAs. Adenosine deaminase acting on RNA-1 (ADAR1), as an RNA-editing factor, reduces circRNA expression. Several studies have found that ADAR1 negatively modulates circRNA formation by interacting with DExH-box helicase 9 (DHX9) [19] and androgen receptor [20].

### Function of circRNAs

After their discovery, circRNAs were misunderstood as the result of splicing errors. With the development of gene sequencing and other technologies, studies have found that circRNAs are involved in biological processes by being translated into peptides [21–24], binding to RBPs [25, 26], and sponging miRNAs [27, 28]. Among

### Table 1: Online circRNA databases

| Name       | Description of the database                                      | Website address                                  | Reference |
|------------|------------------------------------------------------------------|--------------------------------------------------|-----------|
| circBase   | Database of circRNAs from different species                      | http://www.circbase.org/                         | [31]      |
| circNet    | Database of circRNAs originated from transcriptome sequencing data | http://circnet.mbc.nctu.edu.tw/                  | [32]      |
| starBase   | Database of circRNA-miRNA interactions                           | http://starbase.sysu.edu.cn/                     | [33]      |
| deepBase   | Database of IncRNAs and circRNAs                                | http://rna.sysu.edu.cn/deepBase/                 | [34]      |
| circ2Traits| Database of circRNA-related diseases                             | http://gyanxet-beta.com/circdb/                 | [35]      |
| TSCD       | Database of tissue-specific circRNA                              | http://gb.whu.edu.cn/TSCD/                       | [36]      |
| CSCD       | Database of cancer-specific circRNA                              | http://gb.whu.edu.cn/CSCD                        | [37]      |

### Table 2: EMT-related circRNAs acting through WNT signaling

| circRNA        | Expression pattern | Interaction with WNT signaling | Sponged miRNA | Cancer type | Reference |
|----------------|--------------------|---------------------------------|---------------|-------------|-----------|
| CircRNA-100290 | Up                 | Activate                        | miR-516b      | CRC         | [74]      |
| CircRNA-NEK6   | Up                 | Activate                        | miR-370-3p    | TC          | [75]      |
| Circ_0000177   | Up                 | Activate                        | miR-638       | Glioma      | [76]      |
| Circ_CBFB      | Up                 | Activate                        | miR-607       | CLL         | [77]      |
| Circ_0001946   | Up                 | Activate                        | miR-13a-5p    | LAC         | [94]      |
| CircRNA_102171 | Up                 | Activate                        | –             | PTC         | [99]      |
| Circ_0006427   | Down               | Inhibit                         | miR-6783-3p   | LUAD        | [80]      |
| Circ_0000523   | Down               | Inhibit                         | miR-31        | CRC         | [81]      |
| Circ-ITCH      | Down               | Inhibit                         | miR-214       | Glioma      | [90]      |
| Circ-ITCH      | Down               | Inhibit                         | miR-214, miR-17| TNBC       | [89]      |
| Circ_0002052   | Down               | Inhibit                         | miR-1205      | OS          | [85]      |

CRC: Colorectal cancer, TC: Thyroid cancer, CLL: Chronic lymphocytic leukemia, LAC/LUAD: Lung adenocarcinoma, PTC: Papillary thyroid cancer, TNBC: Triple-negative breast cancer, OS: Osteosarcoma
these processes, circRNAs most commonly act as miRNA sponges in tumor cells. CircRNAs have many miRNA binding sites. CircRNAs are often negatively correlated with miRNAs and repress miRNA activity. For example, circPRMT5 facilitates urothelial carcinoma of the bladder (UCB) cell metastasis by sponging tumor-suppressor miR-30c [9]. However, Piwecka M et al. illustrated that circRNAs can positively modulate miRNAs and decrease miRNA downstream genes [29]. CircRNAs can interact with RBPs, thus affecting nuclear translocation and modulating the targeted pathway. CircRNAs can also play a protein-coding role. Several studies on protein-coding circRNAs, which can be translated into peptides by binding to ribosomes, have been performed [21–24].

**Databases of circRNAs**

With the development of high-throughput sequencing technology, numerous circRNAs have been found and reported in databases [30] (Table 1). The circBase database mostly contains circRNAs of different species, such as human, mouse, and *Latimeria* organisms. Sequence information and evidence supporting the expression of circRNAs can be searched and downloaded [31]. The CircNet database includes transcriptome sequencing datasets and data on expression in specialized tissues [32]. The CircNet and starBase databases also provide data on networks between circRNAs, miRNAs, and targeted genes [32, 33]. Information on circRNAs and lncRNAs can also be found in the deepBase database. This database contains the sequencing datasets of a large amount of circRNAs [34]. The Circ2Traits database includes information on RNA-related diseases and RNA traits. It has classified thousands of circRNAs connected to hundreds of diseases [35]. Tissue-specific circRNAs are mostly found in the tissue-specific circRNA database (TSCD). TSCD contains data on the human and mouse genomes [36]. The cancer-specific circRNA database is the first database that fully comprises cancer-specific circRNAs. This database may provide a meaningful strategy for the control of tumor cells [37].

---

![Diagram](image)

**Fig. 1** CircRNA plays an important role in tumor metastasis. During EMT, circRNA absorbing miRNA attenuates the inhibition of the miRNA on EMT-related genes, such as EMT-TF/E-cad, N-cad, vimentin and cdc42. As a result, epithelial cells lose their characteristics, such as cell-to-cell adhesion and cell polarity. Instead, the cells gain motility, migratory potential, and invasive properties, becoming mesenchymal stem cells. In addition, EMT triggers primary tumor cells to enter the circulatory or lymphatic system. Then, circulating tumor cells are transported to distant tissues or organs to form secondary metastatic deposits through EMT. Of note, circRNAs secreted as exosomes are detected in serum/urine, which provides a novel strategy for the diagnosis and treatment of cancer.
Contribution of circRNAs to epithelial-to-mesenchymal transition regulation

Cell–cell contact and cytoskeletal proteins undergo changes during EMT. A decrease in the expression of the epithelial marker E-cad is possibly a significant event, whereas the levels of mesenchymal markers, such as N-cad and vimentin, increase [38–41]. Several EMT-TFs, such as the Snail, Twist, slug, and ZEB families, are known regulators during EMT. They can bind to E-boxes to regulate EMT markers [42–46]. Some signaling pathways, particularly the Wnt/β-catenin, TGF-β/SMAD, and Notch pathways, may induce EMT [39, 47–49]. Here, we provide up to date information on circRNAs involved in EMT mechanisms.

CircRNA control of EMT-TFs

Regulation of snail by circRNAs

Several circRNAs are potentially involved in regulating EMT-TFs, which are considered fundamental players in EMT. Snail is an EMT-TF and is positively correlated with EMT progression [50, 51]. For example, circRNA_0084043 is significantly upregulated in melanoma tissues. Bioinformatics analysis and luciferase reporter assays have confirmed that circRNA_0084043 directly interacts with miR-153-3p and that Snail is directly targeted by miR-153-3p. Therefore, circRNA_0084043 overexpression upregulates Snail expression and promotes EMT progression. The circRNA_0084043/miR-153-3p/Snail axis is the first discovery in melanoma related to circRNA. CircRNAs provide a potential new use for targeted therapy for melanoma [52]. A human circRNA microarray has been used to explore the upregulated circRNA_000284 in cervical cancer cells. Similarly, miR-506 has been identified as a circRNA-000284-associated miRNA by performing a luciferase reporter assay and through anti-AGO2 RNA precipitation. In addition, Snail-2 has been confirmed as a direct target of miR-506.

As a result, circRNA-000284 can indirectly increase Snail-2 expression and promote invasion, migration, and metastasis. The pro-metastatic effect of circRNA_000284 was experimentally confirmed in cervical cancer cells, which demonstrated in several research reports [18, 63, 66].

Regulation of twist on vimentin by circRNAs

Twist as an important EMT-TF that directly or indirectly governs the transcription of EMT-associated genes, thereby decreasing epithelial markers, such as E-cad, and increasing mesenchymal cell markers, including vimentin [54]. Cullin2 (Cul2) is a core component of multiple ElonginB/C-CUL2/5-SOCS-box protein (ECS) E3 ubiquitin–protein ligase complexes that mediate the ubiquitination of target proteins [55, 56]. A study has validated that Twist1 promotes Cul2 transcription by binding to the Cul2 promoter and increases the pre-mRNA levels of Cul2. As a result, Twist1 upregulates Cul2 circRNA (circRNA_10720) expression. CircRNA_10720 is positively associated with EMT and promotes metastasis in hepatocellular carcinoma (HCC) cells. CircRNA_10720 regulates vimentin by sponging a series of miRNAs. This research hypothesizes that miR-490-5p is the main absorbed miRNA that regulates vimentin, as shown by a luciferase reporter assay. CircRNA_10720 knockdown counteracts the effect of Twist1 by promoting metastasis through the upregulation of vimentin [57]. This process provides a novel mechanism of how Twist regulates vimentin via a circRNA.

TGF-β/Smad pathway-related circRNAs

Previous studies have demonstrated that TGF-β can enhance the EMT process. The TGF-β/Smad pathway has been demonstrated to be a positive regulator in the growth and metastasis of various cancer types [58, 59]. Wang L et al. reported that circPTK2 inhibits non-small-cell lung carcinoma (NSCLC) metastasis by disrupting oncogenic miR-429 and miR-200b-3p and promoting transcriptional intermediary factor 1γ (TIF1γ) expression [60]. TIF1γ, which is considered as a negative regulator of the TGF-β/Smad pathway [61, 62], represses the TGF-β-related EMT. Zeng K et al. demonstrated that the high expression level of circANKS1B can be indicative of a poor prognosis in triple-negative breast cancer (TNBC). The upregulated circANKS1B has been implicated in promoting breast cancer invasion and metastasis. The pro-metastatic effect of circANKS1B is mediated through the interaction with miR-148a-3p and miR-152-3p, thereby increasing upstream transcription factor 1 (USF1) expression [63]. USF1 binds to TGF-β1 in murine tissues [64]. Zeng K et al. confirmed that upregulated USF1 can interact with TGF-β1 in TNBC tissues to substantially upregulate the expression of vimentin, p-Smad2, and p-Smad3 but significantly decrease the expression of E-cad. Moreover, circANKS1B expression is regulated by USF1. USF1 overexpression upregulates circANKS1B expression via the splicing factor Epithelial splicing regulatory protein 1 (ESRP1), showing that a positive feedback regulatory loop is formed between circANKS1B, USF1, and ESRP1 [63]. Splicing factors (SFs) can also regulate circRNA formation and EMT progression by inserting SF-binding motifs into flanking introns, which has been demonstrated in several research reports [18, 63, 65, 66].

Wnt pathway-related circRNAs

In general, the Wnt pathway can be classified as a canonical pathway (Wnt/β-catenin pathway) and a noncanonical pathway (Wnt/PCP and Wnt/Ca pathways). Here, we mainly discuss the canonical Wnt/β-catenin pathway. In brief, in the absence of Wnt signaling, β-catenin, Axin, glycogen synthase...
kinase-3, adenomatous polyposis coli (APC), and casein kinase 1 form a destruction complex in the cytoplasm in which the initially phosphorylated and subsequently ubiquitinated β-catenin is degraded by the proteasome. The presence of Wnt ligands blocks the formation of this complex. As a result, β-catenin accumulates to a certain level in the cytoplasm and then translocated into the nucleus to activate the Wnt-targeted genes [67–70]. The interaction between circRNAs and the Wnt/β-catenin pathway to promote cancer progression has been demonstrated (Table 2).

Frizzled gene family proteins (FZDs) are important cell surface receptors in the Wnt/β-catenin signaling pathway and consists of FZD1/2/3/6/7, FZD5/8, FZD4, and FZD9/10 subfamilies. FZDs are positive membrane receptors in the Wnt/β-catenin pathway and are significantly associated with cancer progression [71–73]. Guan F et al. demonstrated the obvious overexpression of circRNA_100,290 and FZD4 in colorectal cancer (CRC) and found their target relationship with miR-516b. CircRNA_100,290 not only increases proliferation and metastasis by regulating FZD4 but also upregulates the expression of MYC, CCD1, CCD2, TCF7, and SOX4, which are target genes of the Wnt/β-catenin signaling pathway [74]. In thyroid cancer, circNEK6 is a competing endogenous RNA of FZD8 that absorbs miR-370-3p, resulting in the activation of the Wnt/β-catenin signaling pathway. The upregulation of circNEK6 enhances the expression of c-myc and CCD1, whereas silencing FZD8 abrogates their expression [75]. Chen et al. demonstrated that hsa_circ_0000177 is a miR-638 sponge that targets FZD7. Furthermore, hsa_circ_0000177 activates the Wnt/β-catenin pathway and promotes the growth of glioma cells by enhancing FZD7 expression [76]. Xia et al. showed that circ-CBFβ ultimately leads to CLL progression via the FZD3-induced activation of Wnt/β-catenin signaling by sponging miR-607 [77].

Dickkopf-1 (DKK1) can specifically bind to LRP5/6, thereby interfering with the formation of the Wnt-LRP5/6-FZD complex and inhibiting the downstream pathway [78, 79]. Yao Y et al. illustrated that the significantly downregulated circ_0006427 is involved in the tumorigenesis of lung adenocarcinoma (LUAD) by releasing miR-6783-3p and by activating the Wnt signaling pathway through DKK1 knockdown. Circ_0006427 downregulation or DKK1 knockdown promotes cell migration and invasion [80]. Y. Jin et al. demonstrated a significant decrease in hsa_circ_0000523 and DKK1 in CRC and identified their target correlation with miR-31. A decreased DKK1 level not only enhances β-catenin in the nucleus but also promotes CRC proliferation [81].

APC is considered a negative regulator in the Wnt/β-catenin signaling pathway and is associated with the β-catenin destruction complex [82–84]. Hsa_circ_0002052 and APC2 are obviously decreased in osteosarcoma (OS) and are strongly correlated. As a result, the downregulation of hsa_circ_0002052 promotes proliferation and metastasis through the Wnt/β-catenin pathway. MiR-1205 has been identified as a common target miRNA of hsa_circ_0002052 and APC2 and is upregulated in OS. Hsa_circ_0002052 also provides a novel therapeutic target for OS therapy [85].

ITCH is a E3 ubiquitin ligase enzyme and can inactivate the Wnt/β-catenin pathway by degrading phosphorylated dishevelled Dvl [86–88]. Dvl can bind to Axin, which is an important component of the β-catenin destruction complex, to positively modulate the β-catenin level. Several studies have demonstrated the positive relationship between circ-ITCH and ITCH. In TNBC, circ-ITCH exhibits breast tumor inhibition and can promote the expression of ITCH tumor suppressor by absorbing miR-214 and miR-17 [89]. Feng Li et al. illustrated the anti-oncogenic effect of circ-ITCH on glioma. Decreased circ-ITCH and ITCH can promote migration and invasion by sponging miR-214. In this mechanism, miR-214 and miR-17 can bind to the 3′ UTR of ITCH to enhance ITCH expression [89, 90].

Sirtuin 1 (SIRT1) exerts diverse effects on tumor cells as an oncoprotein or tumor suppressor [91–93]. Yao Y et al. demonstrated that circ_0001946 expression is increased in lung adenocarcinoma. Circ_0001946 upregulates SIRT1 and activates the Wnt/β-catenin pathway in LAC by targeting miR-135a-5p, thus promoting LAC progression [94]. However, the mechanism involving circRNA and SIRT1 remains largely unknown.

Previous studies have found that catenin beta-1 (CTNNBIP1) is a negative regulator in the Wnt/β-catenin pathway and can interact with β-catenin. Mechanistically, increasing evidence has shown that the CTNNBIP1/β-catenin interaction can prevent the formation of the β-catenin/TCF/LEF complex. As a result, it prevents the activation of the Wnt/β-catenin signaling pathway [95–98]. The upregulated circRNA_102171 facilitates the malignant behavior of papillary thyroid cancer by regulating the CTNNBIP1-mediated activation of the Wnt/β-catenin pathway. CircRNA_102171 overexpression enhances the β-catenin/TCF/LEF interaction while blocking the association between CTNNBIP1 and β-catenin. Nevertheless, how circRNA_102171 modulates CTNNBIP1 still needs further studies [99].

**Regulation of cell adhesion molecules and cytoskeletal proteins by circRNAs**

In addition to the regulation exerted by circRNAs at the level of transcription factors and EMT-related signaling pathways, certain circRNAs function by directly or indirectly regulating the expression of cell adhesion molecules and cytoskeletal proteins. Such deregulated circRNAs can act either as tumor suppressors or oncogenes to control cell proliferation, migration and metastasis. For example, circ_0058063 promotes bladder cancer progression by sponging miR-145-5p and regulating CDK6 expression [100]. In HCC, the circRNA circMTO1 (mitochondrial
translation optimization 1 homologue) significantly downregulated and circMTO1 overexpression suppressed HCC cell proliferation and invasion by sponging oncogenic miR-9. Moreover, circMTO1 is an important circRNA in bladder cancer tissue. A decreased circMTO1 level was positively correlated with bladder cancer cell metastasis. Further research found that circMTO1 was able to sponge miR-221, and ectopic expression of circMTO1 negatively regulated the E-cad/ N-cad pathway to inhibit bladder cancer cell EMT by competing for miR-221 [101].

Several circRNAs have been demonstrated to regulate vimentin transcription. For instance, Tao Wang et al. reported on the role of circP4HB in NSCLC. In NSCLC, circP4HB levels are significantly higher than in healthy lung. Of note, vimentin has a documented role in promoting EMT and metastasis in NSCLC as a regulator of cell to cell adhesion and cell motility. Interestingly, circP4HB can positively regulate vimentin and enhance EMT and metastatic disease through miR-133a-5p sequestration [102]. A recent circRNA profiling study showed that circRBM23 expression was upregulated, whereas miR-138 expression was decreased, in HCC tissues. Downregulation of circRBM23 decreased cell viability, proliferation, and migration, and promoted the expression of miR-138 and its related target genes vimentin and CCND3 [103]. Thus, the circRNA-miRNA-vimentin regulatory axis in EMT is important for tumor invasion and metastasis.

Protocadherins (PCDHs) are classified as the largest subgroup within the cadherin superfamily of calcium-dependent cell-cell adhesion molecules that are mainly expressed in the nervous system and have been implicated in neural cell-cell interactions. Little is known about the functions of PCDHs, but some members, such as PCDH8 and PCDH10, have been shown to suppress tumor activity [104–107], suggesting that PCDHs may act as tumor suppressors by influencing tumor growth and metastasis. In prostate cancer (PCa), Zhan Yang et al. have shown that an AmotI1-derived circRNA termed circAMOT1L1 is downregulated in PCa and that low expression of circAMOT1L1 facilitates PCa cell migration and invasion by downregulating E-cad and upregulating vimentin, which leads to EMT and PCa progression. Mechanistically, the study demonstrated that circAMOT1L1 serves as a sponge for binding miR-193a-5p in PCa cells, relieving the miR-193a-5p-mediated repression of the Pcdha gene cluster, which is a subset of PCDHs [108].

**Regulation of cell motility and metastasis by circRNAs through rho GTPases**

Carcinoma cells that undergo EMT reorganize the epithelial actin cytoskeleton into one with actin stress fibers and form migratory organelles, such as lamellipodia and filopodia. In this way, cells acquire directional motility and metastatic potential [109]. Rho GTPases belong to the group of small G proteins that cycle between an inactive GDP-bound state and active GTP-bound state. Among the members of the Rho GTPase family, RhoA, cdc42 and Rac have been studied in most detail. RhoA facilitates the formation of actin stress fibers, while cdc42 and Rac1 generally assist in filopodia and lamellipodia formation. Rho-kinase (ROCK), as the downstream effector of RhoA, induces myosin light chain (MLC) phosphorylation by inhibiting MLC phosphatase to enhance myosin contractility. ROCK also activates LIM kinase (LIMK) and then represses coflin. The Rho/ROCK/MLC/myosin and Rho/ROCK/LIMK/cofilin pathways all facilitate stress fiber formation. Moreover, actin polymerization dependent on mDia is an essential factor for the assembly of stress fibers [110, 111]. CircHIAT1 expression was suppressed by androgen receptor (AR) in clear cell renal cell carcinoma (ccRCC). Interestingly, circHIAT1 could stabilize the expression of miR-195-5p/29a-3p/29c-3p as a reservoir. It has been demonstrated that the downregulating miR-195-5p/29a-3p/29c-3p targets the cdc42 3′-UTR to enhance the migration and invasion of ccRCC cells. Notably, upregulation of AR-targeting cdc42 significantly promoted filopodia formation, while the increase could be partially reversed by CircHIAT1 overexpression [112]. Jie Li et al. investigated the role of circ-IARS in pancreatic cancer tissues. Circ-IARS was secreted by pancreatic cancer cells and upregulated in plasma exosomes. Then, circ-IARS enters HUVECs through exosomes. In this study, upregulation of circ-IARS in HUVECs changed their biological functions. It has been demonstrated that circ-IARS sponges miR-122 to increase RhoA activity and F-actin expression and reduce ZO-1 expression. As a result, circ-IARS/RhoA modulates the permeability of the endothelial monolayer to promote metastasis [113].

**Other pathways related to circRNAs**

High-mobility group box 1 (HMGB1) is considered a chromatin-binding factor that regulates HCC progression [114–116]. HMGB1 knockdown can significantly attenuate the migration and invasion behavior [117, 118]. Li S et al. demonstrated the correlation between a circRNA and the HMGB1/RAGE pathway. Upregulating circRNA_101,368 suppresses miR-200a expression, thus enhancing the metastasis of HCC cells by activating the miR-200a-mediated HMGB1/RAGE pathway [119].

MiR-7 is considered a tumor cell suppressor whose dysregulation facilitates malignant behavior [120, 121]. The experimental basis for the targeted treatment from the perspective of the circRNA CDR1as/miR-7 pathway has been validated in several cancer cells. Su C et al. demonstrated that the remarkably increase in ciRS-7 (circRNA CDR1as) induces the metastasis of NSCLC cells through the miR-7 downstream NF-κB pathway [122]. Furthermore, the circRNA CDR1as/miR-7 pathway regulates the EMT...
phenotype. Furthermore, a miR-7 inhibitor can enhance the metastatic ability of HCC and OS cells [123, 124].

Yu J et al. linked the circRNA cSMARCA5/miR-17-3p/miR-181b-5p/TIMP3 regulatory pathway to EMT in HCC [125]. TIMP3 has been reported to be a tumor cell suppressor in several studies and inactivates the EMT program [126, 127]. It has been found that the decrease in circRNA cSMARCA5 facilitates HCC cell migration and metastasis and downregulates TIMP3 transcription by absorbing miR-17-3p and miR-181b-5p [125].

Human mesenchymal stem cells (MSCs) are multipotent cells that possess the ability to self-renew and differentiate into mesodermal lineage cells [128, 129]. Due to this differentiation potential and other properties to regenerate injured tissues indirectly via growth factor secretion and immunomodulation, MSCs hold promise for regenerative medicine. A full understanding of the molecular mechanisms that regulate the maintenance of human MSC identity and their uncommitted state is helpful for improving therapeutic efficacy. Stem cell plasticity and identity are controlled by master regulatory genes and complex circuits involving noncoding RNAs [130–132]. Alessandro Cherubini et al. showed that compared to that in differentiated mesodermal cells, circFOX1P1 levels were enriched in MSCs. The authors demonstrated a direct interaction between circFOX1P1 and miR-17-3p/miR-127-5p, which resulted in the modulation of the EGFR and noncanonical Wnt pathways. They found a regulatory role for circFOX1P1 as a gatekeeper of pivotal stem cell molecular networks [133]. Yanjie Wang et al. demonstrated that circRNA_014511 could affect the expression of P53, regulate cell apoptosis and cell cycle arrest, and influence the radiosensitivity of bone marrow mesenchymal stem cells (BMMCs) by adsorbing miR-29b-2-5p. Furthermore, Yan-Jing Zhu et al. found that circZKSCAN1 suppressed cell stemness in HCC by regulating the function of the RBP fragile X mental retardation protein (FMRP), whose downstream target gene is cell cycle and apoptosis regulator 1 (CCAR1) and showed that CCAR1 acts as a coactivator of the Wnt/β-catenin signaling pathway and upregulates cell stemness [134].

Conclusions and future perspectives

Metastasis is an important factor causing malignant tumor behavior. A number of circRNAs have been correlated with tumor cell EMT regulation (Fig. 1). CircRNAs are closely associated with tumor progression and patient prognosis. However, unlike studies on other noncoding RNAs, further efforts are needed to produce several EMT-related circRNAs. Furthermore, this work is the first review on the associations between circRNAs and EMT. The exact mechanisms of how circRNAs regulate EMT remain unclear. CircRNA-based diagnostics and treatments have many challenges. The former involves a low circRNA expression level and advanced detection measures. The latter includes the requirement of safety and effectiveness and the absence of off-target effects. CircRNAs are promising novel cancer markers because of their ribonuclease insensitivity and widespread expression in body fluids. Some studies have suggested that exosomal circRNAs are stable. Thus, future studies should further develop several EMT-related circRNAs associated with various types of cancers and characterize the function of circulating circRNAs, especially exosomal circRNAs, to make a potent therapy to directly target circRNAs. Overall, identifying the specific functions and mechanisms of circRNAs in EMT will provide novel and powerful perspectives on tumor management.

Abbreviations

ADAR1: Adenosine deaminase acting on RNA-1; APC: Adenomatous polyposis coli; AR: Androgen receptor; BMMCs: Bone marrow mesenchymal stem cells; CCAR1: Cell cycle and apoptosis regulator 1; circRNA: Circular RNA; ciRNA: Circular intron RNA; CRC: Colorectal cancer; CTNNBIP1: Catenin beta-1; Cul2: Cullin2; DEX: Dexamethasone; DKK1: Dickkopf-1; E-cad: E-cadherin; eRNA: Exon circRNA; ECS: Bonginib/β-CUL2/S-SCs-box protein; BcRNA: Exon–intron circRNA; EMT: Epithelial-to-mesenchymal transition; EMT-TFs: EMT transcription factors; ESRP1: Epithelial splicing regulatory protein 1; FMRP: Fragile X mental retardation protein; FZDs: Frizzled gene family proteins; HCC: Hepatocellular carcinoma; HMGB1: High-mobility group box 1; LIMK: LIM kinase; LUAD: Lung adenocarcinoma; MLIC: Myosin light chain; MSCs: Human mesenchymal stem cells; N-cad: N-cadherin; NSCLC: Non-small-cell lung carcinoma; OS: Osteosarcoma; Pca: Prostate cancer; Pcdha: Protocadherin family proteins; Pdcdg: Protocadherin-q; RBP: RNA binding protein; ROCK: Rho-kinase; SFs: Splicing factors; SIRT1: Sirtuin 1; TGF-β: Transforming growth factor β; TIF1γ: The transcriptional intermediary factor 1γ; TNBC: Triple-negative breast cancer; TSCD: Tissue-specific circRNA database; UCB: The urothelial carcinoma of the bladder; USF1: The upstream transcription factor 1

Acknowledgements

Not applicable.

Authors’ contributions

BG-S, ML-L and HY-Q were major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81874183, 81872304 and 81572845), the Jiangsu Provincial Key Medical Discipline, and the Project of Invigorating Health Care through Science, Technology and Education (NO. ZDKX2016014, ZDKC2016009), and the Qing Lan Project.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou 221002, Jiangsu Province, China. 2Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
Received: 22 June 2019 Accepted: 9 September 2019

References

1. Matoba R, Marizane Y, Shiode Y, Hirano M, Doi S, Toshima S, Araki R, Hosogi M, Yonesawa T, Shigara S. Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in retinal pigment epithelial cells. PLoS One. 2017;12:e0181481.

2. Sakabe M, Ikeda K, Nakatani K, Kawada N, Imanaka-Yoshida K, Yoshida T, Yamagishi T, Nakajima Y. Rho kinases regulate endothelial invasion and migration during valvuloseptal endocardial cushion tissue formation. Dev Dyn. 2006;235:94–104.

3. Feldkoren B, Hutchinson R, Rapporto Y, Mahajan A, Zitnik M, Int. open signals transforming growth factor-beta 1 (TGF-beta 1) dependent down-regulation of E-cadherin expression - important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma. Exp Cell Res. 2017;355:57–66.

4. Nishiyama M, Tsunedomi R, Yoshimura K, Hashimoto N, Matsukuma S, Arai T, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852–6.

5. Kolakofsky D. Isolation and characterization of Sendai virus DI-RNAs. Cell. 1976;8:547–55.

6. Sanger Hl, Rittig R, Greiner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:996–1000.

7. Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW, Vogelstein B. Scrambled exons. Cell. 1991;64:607–13.

8. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Non small cell lung cancer (NSCLC) cells: EMT-MES5 cells migrate on collagen and fibronectin more efficiently than wild-type cells. Cancer Res. 1997;57(10):2149–55.

9. Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant paired rod-like structures. Proc Natl Acad Sci U S A. 1976;8:547–55.

10. Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant paired rod-like structures. Proc Natl Acad Sci U S A. 1976;8:547–55.

11. Conn SJ, Pillman KA, Toubia J, Conn VM, Salaminidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–36.

12. Khan MA, Reckman YJ, Aufiero S, van den Hoogenhof MM, van der Made I, Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis. 2017;8:e3171.

13. Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015;21:172–9.

14. Yen Y, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110(3):304–15.

15. Legnini I, Di Tomiteo G, Rossi F, Morlando M, Brignati F, Standler Q, Fatica A, Santini T, Andronache A, Wade M, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66:22–39.

16. Granados-Riveron JT, Aquino-Arguin G. The complexity of the translation ability of circRNAs. Biochim Biophys Acta. 2016;1859:1245–51.

17. Yang Z, Du WW, Wu Y, Yang Z, Awan FM, Li X, Yang W, Zheng C, Yang Y, Qee A, et al. A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing cardiac repair. Theranostics. 2017;7:3842–55.

18. Yang Z, Awan FM, Du WW, Zeng Y, Liu J, Wu GS, Yang W, Yang BB. The circular RNA interacts with STAT3, increasing its nuclear translocation and wound repair by modulating Dnmt3a and miR-17 function. Mol Ther. 2017;25:2062–74.

19. Han D, Li J, Wang H, Su X, Hou J, Gu Y, Qian C, Lin Y, Liu X, Huang M, et al. Circular RNA circMT01 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151–64.

20. Hansen TB, Jensen TI, Clausen SH, Bramsen JB, Finsen B, Darnagaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.

21. Pliwecka M, et al. Loss of a bacterial circular RNA locus causes miRNA deregulation and affects brain function. Science. 2017;357(6357).

22. Szabo I, Salzman J. Detecting circular RNAs: bioinformatic and experimental challenges. Nat Rev Genet. 2016;17(6):579–92.

23. Glazer P, Papavasileiou P, Rajewsky N. cBase: a database for circular RNA. RNA. 2014;20:1666–70.

24. Liu YC, Li JR, Wu GS, Yang W, Yang B. The epithelial-mesenchymal transition and are dependent on the transcriptional co-regulatory activity of E-cadherin. Oncogene. 2009;28(38):4926–37.

25. Yang ZG, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110(3):304–15.

26. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Nat Cell Biol. 2006;8:547–55.

27. Yagi H, et al. Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells. Cancer Sci. 2018;109(1):110–9.

28. Kolakofsky D. Isolation and characterization of Sendai virus DI-RNAs. Cell. 1976;8:547–55.

29. Sanger Hl, Rittig R, Greiner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852–6.

30. Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW, Vogelstein B. Scrambled exons. Cell. 1991;64:607–13.

31. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Non small cell lung cancer (NSCLC) cells: EMT-MES5 cells migrate on collagen and fibronectin more efficiently than wild-type cells. Cancer Res. 1997;57(10):2149–55.

32. Khan MA, Reckman YJ, Aufiero S, van den Hoogenhof MM, van der Made I, Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis. 2017;8:e3171.

33. Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015;21:172–9.
activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem. 2012;287:7026–38.

48. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101:816–29.

49. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:188–219.

50. Stanisavljevic J, Loubat-Casanovas J, Herrera M, Luque T, Pena R, Lluch A, Albanel J, Bonilla F, Rovira A, Pena C, et al. Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis. Cancer Res. 2015;75:284–95.

51. Millanes-Romero A, Herranz N, Penera V, Iturbide A, Loubat-Casanovas J, Gil J, Jeneuwein T, Garcia de Herreros A, Peiro S. Regulation of heterochromatin transcription by Snail1/AUX/2 during epithelial-to-mesenchymal transition. Mol Cell. 2013;52:746–57.

52. Luan W, Shi Y, Zhou Z, Xia Y, Wang J. circRNA_0084043 promotes malignant melanoma progression via miR-153-3p/Snail axis. Biochem Biophys Res Commun. 2018;502:222–9.

53. Ma HB, Yao YN, Yu JL, Chen XL, Li HF. Extensive profiling of circular RNAs and the potential regulatory role of circRNA_0002084 in cell proliferation and invasion of cervical cancer via sponging miR-506. Am J Transl Res. 2018;10:592–604.

54. Shibue T, Weinberg RA. EMT and cell cycle: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–29.

55. Cai W, Yang H. The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. Cell Div. 2016;1:17.

56. Petrakos MD, Delaere RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.

57. Meng J, Chen S, Han JX, Qian B, Wang XR, Zhong WQ, Qin Y, Zhang H, Gao WF, Lei YL, et al. Twist1 regulates vimentin through C/EBP beta-catenin to promote epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Res. 2018;78:4510–62.

58. Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT. JAK2/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014;44:1643–51.

59. Massague J. TGFbeta in Cancer. Cell. 2008;134:215–30.

60. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al. Circular RNA has_circ_0008305 (circPTK2) inhibits TGF-beta-induced epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer. Mol Cancer. 2018;17:140.

61. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Wang L, Tong X, Zhou Z, Yang H, Liu Z, Zhao J, et al. JAK/STAT3 signaling promotes epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in colorectal cancer cells by inhibiting Wnt signaling. Biochem Biophys Res Commun. 2018;508:347–53.

62. Jin Y, Yu LL, Zhang B, Liu CF, Chen Y. Circular RNA_hsa_circ_000523 regulates proliferation and apoptosis of colorectal cancer cells as miRNA sponge. Braz J Med Biol Res. 2018;51:781–11.

63. Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, Liu X, Sun H, Pan Y, Wang S. The role of upstream stimulatory factors in colorectal cancer cells by targeting FZD7/Wnt signaling. Biochem Biophys Res Commun. 2018;503:385–90.

64. Semenov MV, Tamaki K, Brott BK, Mokul S, He X. Head inducer Dickkopf-1 is a ligand for Wnt receptor LRP6. Curr Biol. 2001;11:591–61.

65. Mao B, Wu W, Li Y, Hoppe D, Stannke P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:521–5.

66. Yao Y, Hua Q, Zhou Y. CircRNA has_circ_0006627 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2019;508:347–53.

67. Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT. JAK2/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014;44:1643–51.

68. Colnot S, Deaens T, Niwa-Kavakiita M, Godard C, Harmand G, Kahn A, Giovinnani M, Perret C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A. 2004;101:17216–21.

69. Wu Z, Shi W, Jiang C. Overexpressing circular RNA has_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/beta-catenin pathway by regulating miR-1205/AC2 axis. Biochem Biophys Res Commun. 2018;502:465–71.

70. Huang G, Zou H, Shi Y, Wu W, Cai H, Chen X. Ct-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/beta-catenin pathway. PLoS One. 2015;10:e0131225.

71. Wan L, Zhang L, Fan K, Cheng Z, Sun QC, Wang J. Circular RNA-ITCH suppresses lung Cancer proliferation via inhibiting the Wnt/beta-catenin pathway. Biomed Res Int. 2016;2016:1579490.

72. Liu W, Li M, Wang J, Nie F, Li L. The E3 ubiquitin ligase ICHC negatively regulates canonical Wnt signaling by targeting dishevelled protein. Mol Cell. 2012;32:3903–14.

73. Wang ST, Liu LB, Li MX, Wang YF, Xie PJ, Li Q, Wang R, Wei Q, Kang YH, Meng R, Feng XH. Ct-ITCH regulates triple-negative breast cancer progression through the Wnt/beta-catenin pathway. Neoplasia. 2019;21:232–49.

74. Li F, Ma K, Sun M, Shi S. Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression. Am J Transl Res. 2018;10:1373–86.

75. Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA, Pruitt K. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A. 2010;107:9216–21.

76. Liu S, Yang H, Hu B, Zhang M. Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/beta-catenin signaling pathways. Exp Ther Med. 2017;14:5057–62.

77. Wu Q, Yang W, Qian M, Qiao Y, Zou S, Chen C, Zhang X, Chen Y, Zhao Y, Zhu G, et al. Sirt1 suppresses Wnt/beta-catenin signaling in liver cancer cells by targeting betaCatenin in a PKA-dependent manner. Cell Signal. 2017;37:62–73.

78. Yao Y, Hua Q, Zhou Y, Shen H. CircRNA has_circ_0001946 promotes cell proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/beta-catenin pathway. Biochem Biophys Res Commun. 2018;503:385–90.

79. Semenov MV, Tamaki K, Brott BK, Mokul S, He X. Head inducer Dickkopf-1 is a ligand for Wnt receptor LRP6. Curr Biol. 2001;11:591–61.

80. Mao B, Wu W, Li Y, Hoppe D, Stannke P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:521–5.

81. Yao Y, Hua Q, Zhou Y. CircRNA has_circ_0006627 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2019;508:347–53.
96. Kosari-Monfared M, Nikkakhsh N, Fattahi S, Ghadami E, Ranaei M, Taheri H, Amjadi-Mohef B, Godazdeh GA, Shafaei S, Pilehlijian-Langroudi M, et al. CTNNB1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. J Cell Physiol. 2019;234:2895–904.

97. Q W, Chen J, Cheng X, Huang J, Xiang T, Li Q, Long H, Zhu B. Targeting the Wnt-regulatory protein CTNNB1 by microRNA-214 enhances the Sternness and self-renewal of Cancer stem-like cells in lung adenocarcinomas. Stem Cells. 2015;33:3423–36.

98. Guo M, Zhang X, Wang G, Sun J, Jiang Z, Khasharadian K, Yu S, Zhao Y, Xie C, Zhang K, et al. miR-603 promotes glioma cell growth via Wnt/beta-catenin pathway by inhibiting WIFI and CTNNB1. Cancer Lett. 2015;360:76–86.

99. Bi W, Huang J, Nie C, Liu B, He G, Han J, Fang R, Ding Z, Xu J, Zhang J. CircRNA circRNA_101771 promotes papillary thyroid cancer progression through modulating CTNNB1-dependent activation of beta-catenin pathway. J Exp Clin Cancer Res. 2018;37:275.

100. Sun M, Zhao W, Chen Z, Li M, Li S, Wu B, Bu R. Circ_0058063 regulates CDK6 to promote bladder cancer progression by splicing mir-145-5p. J Cell Physiol. 2019;234:8412–24.

101. Li Y, Wan B, Liu L, Zhou L, Zeng Q. Circular RNA circRTO1 suppresses bladder cancer metastasis by splicing mir-221 and inhibiting epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2019;508:991–6.

102. Wang T, Wang X, Du Q, Wu N, Liu X, Chen Y, Wang X. The circRNA circP4HB promotes NSCLC aggressiveness and metastasis by splicing mir-133a-5p. Biochem Biophys Res Commun. 2019;513:904–11.

103. Wang B, Chen H, Zhang C, Yang T, Zhao Q, Tan Y, Zhang Y, Xu F. Effects of hsa- circ89423 on hepatocellular carcinoma cell- viability and migration as produced by regulating miR-138 expression. Cancer Biother Radiopharm. 2018;33:194–202.

104. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Ceng H, Tian LW, Wong YP, Tong JH, Ying JM, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136:640–651 e641.

105. Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai HH, Sarkar A, Barisch J, Vuzinovirta R, Jones C, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 3q31 in Wilms’ tumor. PLoS Genet. 2009;5:e1000745.

106. Ying Y, Li H, Seng TJ, Lean KL, Song M, Sun J, Jiang Z, Li CM, Su T, Wang X, Keniry M, et al. Dysregulation of p53-RBM25-mediated circAMOTL1-KL downregulation is associated with tumor grade and viral infections in gastric cancer. Proc Natl Acad Sci U S A. 2010;107:4872–7.

107. Yu BF, Wu J, Zhang Y, Sung HW, Xie L, Li RK. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25:1070–80.

108. Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25:1070–80.

109. Yu BF, Wu J, Zhang Y, Sung HW, Xie L, Li RK. Ultrason sound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced anti-tumor effects in hepatoma. Cancer Gene Ther. 2013;20:929–70.

110. Xu B, Yang T, Zhang W, Zhang Y, Liu S, Shen M. CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. Cancer Manag Res. 2018;10:4871–80.

111. Xu Y, Xu QG, Wang ZQ, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F, Zhou WP. Circular RNA CMA/RAS inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.

112. Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA CDR1as acts as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS One. 2016;11:e0158347.

113. Xu B, Yang T, Zhang W, Zhang Y, Liu S, Shen M. CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. Cancer Manag Res. 2018;10:4871–80.

114. Xu Y, Xu QG, Wang ZQ, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F, Zhou WP. Circular RNA CMA/RAS inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.

115. Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA CDR1as acts as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS One. 2016;11:e0158347.

116. Xu B, Yang T, Zhang W, Zhang Y, Liu S, Shen M. CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. Cancer Manag Res. 2018;10:4871–80.

117. Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA CDR1as acts as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS One. 2016;11:e0158347.